

CRD

AtGEX1	MDRFSRKCLLFLLLIILLDPL--TCHSWGWFSSSSSAEDPYSSS----	FSRSRKSNPDFSMEVFSQDKAVQVLE--NKLVLG	LTSCWQNAYSYLLLAGCKETIATEEKR	101
BrGEX1	MDHFKRRYLLFL-LITLIDSP-----PS---	SSRSRIKSNTESIEVSDFDKKAVQVLEDAKNKL	AGPNSCWQNAYGYLLSGCKGMVATEEQR	99
OsGEX1	MRRHAGTIIILLLILACLWLCPGRSSGF	SWNIFSSSSSSPPTAGESRAAPMLEDGAVADFLMDGADDPRAVKLLENARSKLA	GAPSNCWQEAYRRLFASCGDIMADKEMQ	110

AtGEX1	KRFAWYLSDCFIKDSGRPAFPPTCKDESVMMSCLKLDDEHKIYLDFLLETNTICQQQLQSNAFKNE	EIERLVNELKNTAQYTEDKLIDILESKSDALIQTSSMIHDSLGSLD	211
BrGEX1	KRFAWHLSDCFQKESGRPDPTCNDQTMMSCLKKLDDHEHKIYLEFMLETNTICQQQLQSNAFKNE	EIERLVNDLKRSQAQNTTEKLIDILESKSDDLQGTSKIHESVGLID	209
OsGEX1	SRLAWHLSSCFQEDSGRPPFPRCGEVSDMVHCRKRLGVSEDQVFLEFFNTLCHQLQAEAFKH	INTERLVNDLTRTSKSAEEKLEVIEERSDQIIQESRKVQETISSIE	220

AtGEX1	VRVQNVASVTNTLETSVSGLSQQTVEISQEQQKNAIESQLARDGQVKMKETLKDGMDMFLDAYTNIQEGVDKLKSDEQIEVEISVLGNNLSTKMIDLQSTTDDIGTKTR	321
BrGEX1	VVVNNVAHKNTNTIGTQMSGLSQQTRDIYQEQQKITESQLALKEGQEKMGAEAMKVGMEMFNDSVTDKDGVDRKLNDTKQIGGKINQLGEKMSEKMTALENQTSIIGTMTN	319
OsGEX1	MQADHLLAEASKNVGDQIDDVLAHSKAIFEQSKIEADSQAKLREGQTEMRETIAGMTHIQESYESLGNGMDKLKEEAVDIQREIKTVGDSMSTKMQDLQSTANDIGSVAG	330

AtGEX1	SSLDKQQKLLDGQTVALDGIQFLTRFQSEALQESRNTLQRLKEFSQEQQEDLAKRQEKLQEVHDHLFENSKSMLEAQVAFEAKQANMFVALDKLFALHNAMLLESRVVIKA	431
BrGEX1	STLDNQQKLLLEGQSVAIDSQIQLNQFQSEALQESRSTLQRFAEFSQEQQEDLAKRQEQLQVHDHLFENSKSMIAAQEAFAEKQASMFVALDKLFALHNAMLLESRVVIKA	429
OsGEX1	KSLENQMQLLDGQSKAMDGLNNLYSFQAAQALEEESRETIVQKLAQFGQRQQEELLSRQEEIRQAHEHLLIHNSHSILEAQEEFRAKQANIFAALDKLYILHNAILAESRFIKA	440

AtGEX1	FVIYFLSIFVIYMFSTKQTYIIRPRLYIGLCVTLALEVASLRYVN-DTERQAWMIN---LIRSLFALLASAQLLHAALSYRDYEVLNHQILLRLVDKVNDMQSKK---	533
BrGEX1	FFIYFLSIFVIYMFSTKQTYTIRPRLYIGLCVTLALEVASLRYVN-DEEHRAWVIN---VRLSLFAVLASAQLLHSFTYRDYEVLNHILLRLVDKVNSMQSKR---	531
OsGEX1	FFFYCCIVFLIYMLTSAKQTFSIRGHLYFGLCITLLEIGLIKLGADDIDKQFWVISKVFVRSVFLALATVQMLHAIIFTFRDYELLNHHLQTLVEKVRALLEETAAAGE	550

AtGEX1	-ELSYDE---DTESEVDWTSWVDTDLTDDDDNLADPDYKIPPLLIKDNPVTT-----SSLTRRLYNFRPR-----	593
BrGEX1	-EILWDE---DTDSEVDWNSWIDTDITDDDSLGDPDYRIPEQIKDNVGFT-----SSMTKRLYNLRPR-----	591
OsGEX1	KMLPYGGGAESESRLMDYSWVFDLAEDEVDSNADPSYALPGDEQRQVAVVAPRRRHASCPEEVVGENSITSAGRRYNLRPRSSYRQT	639

	% identity	
	BrGEX1	OsGEX1
AtGEX1	73.81	43.84
BrGEX1		42.13

Figure S1. Sequence alignment of AtGEX1 (At5g55490), BrGEX1(XP_009120059) and OsGEX1 (XP_015611623). Alignment was performed using Clustal Omega (<https://www.ebi.ac.uk/Tools/msa/clustalo/>). Amino acid residues that do not match with AtGEX1 are highlighted in pink. CRD is shown as a box. Percent identities between each sequence are shown below the alignment

Table S1. PCR Primers Used for Plasmid Construction.

Name	sequence (5'-3')
BrGEX1F1	GCCGCCCCCTTACCATGGATCATTAAAAGAAG
BrGEX1R1	GGCGCGCCCACCCCTTATCGTGGACGGAGATTGT
OsGEX1F2	GCCGCCCCCTTACCATGAGGAGACACGCAG
OsGEX1R2	GGCGCGCCCACCCCTTCACGTCTGCCTGTAACTACTCCG

Table S2. PCR Primers Used for Quantitative Real-Time PCR.

Gene name	Direction	Sequence (5'-3')
<i>AtGEX1</i> (At5g55490)	Forward	GGCTTTACATTGGTTGTGCG
	Reverse	ACTTCATAGTCCCTGTATGACAAAG
<i>UBQ10</i> (At4g05320)	Forward	GCCCTTGTATAATCCCTGATGAATAAG
	Reverse	AAAGAGATAACAGGAACGGAAACATAGT
<i>BrGEX1</i>	Forward	TCTGTCACTGACGTCAAGGTAGG
	Reverse	TCTCCAACGCAGTCATCTTCTC
<i>OsGEX1</i>	Forward	GAGAGCCTGGCAATGGGAT
	Reverse	ATGCCCTTGCTCTGTCCATC